Related Experiment Videos
A peptide derived from apoptin inhibits glioma growth
Liqiu Zhang1, Hengyu Zhao2, Zhongqi Cui3
1Teaching Experiment Center of Biotechnology, Harbin Medical University, Harbin, P.R. China.
Abstract:
Glioblastoma (GBM) is associated with poor prognosis due to its resistance to surgery, irradiation, and conventional chemotherapy. Thus, efficient therapeutic approaches for the treatment of GBM are urgently needed. HSP70 is an antiapoptotic protein that participates in the inhibition of both mitochondrial and membrane receptor apoptosis pathways and is highly expressed in glioma tissues. Here, we investigated a derivative of apoptin; specifically, a chicken anemia viral protein with selective toxicity toward cancer cells that can inhibit hyperactive molecules, including HSP70. Our earlier studies demonstrated that apoptin directly binds to the promoter of HSP70 and inhibits HSP70 transcription, which contributes to HSP70 downregulation. This study provides the first demonstration of the therapeutic potential of an apoptin-derived peptide for the treatment of GBM by identifying the minimal region of the apoptin domain required for interaction with the heat-shock element (HSE). This apoptin-derived peptide (ADP) inhibits glioma cell proliferation and tumor growth as well as exhibits an increased ability to promote apoptosis in GBM cells compared with rapamycin and temozolomide. ADP treatment inhibited xenograft tumor growth and increased the overall health and survival of nude mice implanted with GBM cells. These effects were measured in tumors obtained from cell lines and were observed in both intracranial and subcutaneous xenografts. In conclusion, we provide the first demonstration that ADP has therapeutic potential for the treatment of human GBM. Specifically, this study suggests that ADP is a potent candidate for drug development based on its favorable toxicity and pharmacokinetic profiles as well as its time- and cost-saving benefits.
Insights
A novel apoptin-derived peptide (ADP) shows promise for treating glioblastoma (GBM). This peptide effectively inhibits glioma cell growth and promotes apoptosis, offering a potential new therapeutic strategy for this aggressive brain cancer.
Area of Science:
- Oncology
- Molecular Biology
- Virology
Background:
- Glioblastoma (GBM) presents a poor prognosis due to resistance to standard treatments.
- Heat shock protein 70 (HSP70) is highly expressed in gliomas and promotes cancer cell survival by inhibiting apoptosis.
- Targeting HSP70 is a potential therapeutic strategy for GBM.
Purpose of the Study:
- To investigate the therapeutic potential of an apoptin-derived peptide (ADP) for GBM treatment.
- To identify the minimal region of apoptin required for interaction with the heat-shock element (HSE) of HSP70.
- To evaluate ADP's efficacy in inhibiting glioma cell proliferation, promoting apoptosis, and reducing tumor growth.
Main Methods:
- Investigated an apoptin derivative, a chicken anemia viral protein, for its selective toxicity toward cancer cells.
- Identified the minimal apoptin domain interacting with the heat-shock element (HSE).
- Assessed ADP's effects on GBM cell proliferation, apoptosis, and tumor growth in vitro and in vivo xenograft models.
Main Results:
- The apoptin-derived peptide (ADP) demonstrated selective toxicity toward cancer cells and inhibited HSP70 transcription.
- ADP significantly inhibited glioma cell proliferation and tumor growth in both intracranial and subcutaneous xenografts.
- ADP treatment increased apoptosis in GBM cells and improved the overall health and survival of tumor-bearing mice compared to rapamycin and temozolomide.
Conclusions:
- The apoptin-derived peptide (ADP) exhibits significant therapeutic potential for human glioblastoma (GBM).
- ADP effectively inhibits tumor growth and promotes apoptosis in GBM models.
- ADP represents a promising candidate for drug development due to its efficacy and favorable profiles.